Broker Center sponsored links

Mylan gets FDA OK for generic Metaglip

Fri Apr 13, 2007 9:48am EDT
 
Email | Print | | Reprints | Single Page
[-] Text [+]

April 13 (Reuters) - Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research, Stock Buzz) said its Mylan Pharmaceuticals Inc. unit received U.S. regulatory approval for its generic version of Bristol-Myers Squibb's (BMY.N: Quote, Profile, Research, Stock Buzz) diabetes drug Metaglip.

Mylan got marketing approval from the U.S. Food and Drug Administration for Glipizide and Metformin Hydrochloride Tablets in 2.5 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg strengths. The product will be shipped immediately, the company said in a statement.

(Reporting by Ankur Relia in Bangalore)

((Editing by Gopakumar Warrier; Reuters Messaging: ankur.relia.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: MYLAN FDA/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS6270

 

Featured Broker sponsored link

Editor's Choice

  • Pictures
  • Video
  • Articles
Photo

A selection of our best photos from the past 24 hours.  View Slideshow 

Most Popular on Reuters

  • Articles
  • Video
  • Recommended
The global destination for corporate leaders, deal-makers and innovators